Identification and Diagnosis of Possible Mutations in Human p53 Lymphocytes in Patients With B-cell CLL

For patients with B-cell chronic lymphocytic leukemia (CLL), an ELISA method proves effective and feasible at identifying patients who are candidates for personalized therapeutic strategies, according to a study presented at the SOHO 2024 Annual Meeting.

Researchers analyzed 20 patients admitted to the hospital with symptoms and clinical features of CLL, such as cough, night sweating, and retrosternal pain. Subsequently, clinical examination and ultrasound revealed adenopathy and/or splenomegaly.

The findings showed that p53 protein concentrations were 20, 15, 18, 40, 10, 12, 14, 60, 30, 10, 13, 15, 10, and 12 µg/dL in men and 140, 30, 13, 20, 25, and 10 µg/dL in women, respectively. The researchers noted that the probability index was P=.034. Moreover, the researchers established a reference interval between 10 and 40 µg/dL, (mean value for men=19.9 µg/dL; women=39.6 µg/dL). The investigators noted that the pathological values reflecting the concentration of mutant p53 protein emphasizes the frequency of CLL with mutant p53 protein being higher in men than women, in a ratio of 2:1, in accordance with data from the specialized literature.

“In the context of B-cell CLL, a simple and inexpensive ELISA method proves useful for identifying patients to be considered as candidates for personalized therapeutic strategies in the presence of p53 protein isoforms,” the researchers concluded.

Reference

Udristioiu A, Cojocaru M, Nica-Badea D. Identification and Diagnosis of Possible Mutations in Human p53 Lymphocytes. Abstract #CLL-042. Presented at the Society of Hematologic Oncology Meeting 2024; September 4-7, 2024; Houston, Texas.